William Hawkins, a pancreatic cancer surgeon and scientist, was named deputy director of MUSC Hollings Cancer Center. In the newly created role, he will focus on strengthening translational research, increasing clinical trials across South Carolina and assisting Craig Lockhart, chief of the Oncology Integrated Center of Clinical Excellence, with making clinical operations more efficient.
Matthew RingelElectra PaskettZihai LiMatthew Ringel, Electra Paskett, and Zihai Li were named deputy directors at The Ohio State University Comprehensive Cancer Center. They will report to OSUCCC Director Raphael Pollock.
Nicholas Petrelli will retire from his leadership position in 2024 after 22 years as Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center and Research Institute at ChristianaCare.
Adebola Adedimeji was named the inaugural associate director of Diversity, Equity, and Inclusion at the Atrium Health Wake Forest Baptist Comprehensive Cancer Center.
Aditya Bardia, a breast medical oncologist and physician scientist who specializes in developing novel targeted and personalized therapies, joined the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center, where he will assume several leadership roles across the institution.
Edna “Eti” Cukierman was named the newly created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research at Fox Chase Cancer Center.
Michelle Bloom was named system director of the Cardio-Oncology Program at NYU Langone Health. The Cardio-Oncology Program provides specialized care to protect patients’ heart health throughout cancer treatment and survivorship.
Ric Downs was named vice president of sales at Fuse Oncology.
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center was awarded two five-year NCI grants totaling more than $3.3 million to expand its summer education programs, which aim to foster an interest in cancer research fields as early as middle school and develop a diverse workforce in cancer research.
Mainz Biomed N.V.’s eAArly DETECT study produced positive topline results.
